Marker Therapeutics, Inc.
Clinical trials sponsored by Marker Therapeutics, Inc., explained in plain language.
A clinical-stage biopharmaceutical company developing cell therapies for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Patient's own t cells engineered to hunt lymphoma in early trial
Cure Recruiting nowResearchers are testing a personalized cell therapy called MT-601 in adults with Hodgkin or non-Hodgkin lymphoma that has come back or stopped responding to treatment. MT-601 is made from each participant's own T cells, which are trained in the lab to recognize several targets fo…
Phase 1 • Sponsor: Marker Therapeutics, Inc. • Aim: Cure
Last updated Sep 17, 2026 00:00 UTC
-
Off-the-Shelf immune cells take on tough blood cancers
Disease control Recruiting nowThis early-stage trial tests a new treatment called MT-401-OTS for people with relapsed acute myeloid leukemia or high-risk myelodysplastic syndromes. The therapy uses donor immune cells specially trained to attack cancer, and is given as a one-time infusion. The main goals are t…
Phase 1 • Sponsor: Marker Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC